Our data and the Recursion OS enable us to train intelligent machine learning models for AI drug discovery and development, which help us rapidly identify new targets and design highly optimized molecules that fuel our pipeline of potential first-in-class and best-in-class medicines.
Leveraging the power of the Recursion OS, we are building an industry-leading pipeline of potential best-in-class and first-in-class therapeutic assets. We focus on indications with high unmet need, including oncology and rare disease.
We are not here to make a few medicines. We are here to reimagine how medicines are made. The Recursion mindset is the deep belief and commitment to industrializing drug discovery through automation, algorithms, and data to deliver on our mission. This is supported by our culture and values.
Recursion leverages sophisticated machine-learning algorithms to distill from its dataset a collection of trillions of searchable relationships across biology and chemistry unconstrained by human bias.
Unlike traditional drug discovery, which begins with a specific target or hypothesis, we leverage the Recursion OS — our drug discovery and development platform for AI in pharma connects technical and scientific tools spanning physical experimentation to in silico analysis.
Through its natural language interface and interactive graphics, LOWE puts state-of-the-art AI tools into the hands of every drug discovery scientist at Recursion in a simple and scalable way.
Salt Lake City , Nov. 04, 2025 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, announced today its participation in the following upcoming investor conferences: Guggenheim 2nd Annual Healthcare Innovation Conference
